Autopsy-confirmed findings linked diagnostic errors, co-pathology, and genetic variation to distinct pathologic patterns across more than 3,300 donors with Parkinsonian disorders.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.